Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28669729 | 1.00 | CA1 (0.53) | CA1CA2CA12CA9CA14 | |
| Water SCHEMBL28670631 | 0.88 | CA1 (0.64) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28139668 | 0.85 | ALDH1A1 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL16031 | 0.85 | — | — | |
| SCHEMBL6423919 | 0.85 | CA1 (0.67) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28198 | 0.85 | CA1 (0.67) | CA1CA2CA12CA9CA14 | |
| Hydrochloric Acid SCHEMBL1162175 | 0.83 | ALDH1A1 (0.52) | CA1CA2CA12CA9CA14 | |
| SCHEMBL26682618 | 0.83 | ALDH1A1 (0.52) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28372761 | 0.83 | ALDH1A1 (0.52) | CA1CA2CA12CA9CA14 | |
| SCHEMBL27830139 | 0.83 | ALDH1A1 (0.52) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE KA RECHERCHE MÉDICALE (FR) | 2018-09-18 | — | — | US | claimed |
| CN-105189614-A | Nanoparticles stabilized with nitrophenylboronic acid compositions | CALIFORNIA INST OF TECHN | 2015-12-23 | — | — | CN | claimed |
| CN-102459167-B | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2015-04-01 | — | — | CN | claimed |
| EP-2421825-B9 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-20 | — | — | EP | claimed |
| EP-2421825-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-01 | — | — | EP | claimed |
| US-8455476-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-06-04 | — | — | US | claimed |
| CN-102459167-A | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2012-05-16 | — | — | CN | claimed |
| EP-2421825-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124108-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| US-5719216-A | IMPROVING STORAGE STABILITY OF POLYMER-MODIFIED BITUMEN BY ADDING AS COMPATIBILIZING AGENT BIS/NITROARYL/ DISULFIDE AND/OR NITROARYL ARYL DISULFIDE | SHELL OIL COMPANY (US) | 1998-02-17 | — | — | US | claimed |
| EP-0756611-A1 | PREPARATION PROCESS FOR POLYMER-MODIFIED BITUMEN | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1997-02-05 | — | — | EP | claimed |
| WO-1996037545-A1 | PREPARATION PROCESS FOR POLYMER-MODIFIED BITUMEN | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1996-11-28 | — | — | WO | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
| EP-0256486-B1 | A METHOD OF PRODUCING ALKALI METAL BENZENESULFINATES | SEITETSU KAGAKU CO. LTD. (JP) | 1990-12-05 | — | — | EP | claimed |
| US-4849138-A | Method of producing alkali metal benzenesulfinates | SEITETSU KAGAKU CO., LTD. (JP) | 1989-07-18 | — | — | US | claimed |
| EP-0256486-A1 | A method of producing alkali metal benzenesulfinates | SEITETSU KAGAKU CO. LTD. (JP) | 1988-02-24 | — | — | EP | claimed |
| US-3992395-A | Process for the preparation of chlorinated phenylhydroxylamines | RHONE-POULENC S.A. (FR) | 1976-11-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | LIPA, MGLL, PNLIP | CA1 4325/4885CA2 2173/4885CA12 2840/4885 |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CA1 4624/4885CA2 2746/4885CA12 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.